Business
NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
Patents valid through 2038Clinical topline results from Phase 2b ALS trial expected in H2 2023CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Patents valid through 2038Clinical topline results from Phase 2b ALS trial expected in H2 2023CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (\"NeuroSense\"), a company developing treatments for severe neurodegenerative diseases, today announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to \"Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.\" The patents relate to NeuroSense's unique fixed-dose combination of ciprofloxacin and celecoxib, two U.S. Food and Drug Administration (FDA) approved drugs that are the active ingredients in PrimeC, the Company's lead drug candidate for treating Amyotrophic Lateral Sclerosis (ALS).\n\nCorresponding patents have been issued in the U.S., Canada, and Australia and are valid through 2038, subject to appropriate maintenance. Additional patent applications relating to the novel formulation of PrimeC and methods for the treatment of other neurodegenerative diseases using NeuroSense's platform of combination therapies including StabiliC and CogniC are pending as well.\n\"We are pleased to receive this most recent patent grant in Europe, Japan, and Israel, which adds to our growing IP estate as we expect the clinical read-out from our PARADIGM Phase 2b study towards year's end. ALS remains a pressing unmet need, and our unwavering commitment to advancing our program, supported by robust intellectual property, underscores our dedication to delivering an effective therapy for individuals battling ALS.\" stated Alon Ben-Noon, NeuroSense's CEO.\nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting mult...